In this webinar we discuss the when and why to use ultrasound enhancing agents (UEAs). This includes when two or more LV segments cannot be visualized adequately for the assessment of LV function (LVEF and RWM assessment) and/or in settings in which the study indication requires accurate analysis of RWMA (JASE 2018). Current information on safety and optimization is discussed and we explore Cardio-Oncology and how best to monitor cardiotoxicity. Lastly, we cover current updates of UEA roles in the evaluation of masses including perfusion techniques.
- When, why, and how should I use ultrasound enhancing
- Current recommendations
- What is it? Why is it important?
- What imaging should I use to monitor for cardiotoxicity?
- 2D, 3D, ultrasound enhancing agents
- Usefulness of Strain
- UEA for mass perfusion
- Thrombus vs Tumor?
- Optimizing perfusion techniques
This program has been designed for sonographers, and other healthcare professionals involved in echocardiography.
This program has been submitted for approval of 0.75 SDMS CME Credit Category AE by the Society of Diagnostic Medical Sonographers (SDMS).
Release Date: 7/8/2020 | Expires: 7/8/2021
Submitted for approval of 0.75 SDMS CME Credit Category AE
Rupal O’Quinn, MD, FACC
- Bracco – honoraria for unrestricted educational conference (ROQ and MM) and consulting in 2018 (ROQ)
- Discussion of off-label use of ultrasound enhancing agents
Michelle McGovern, RDCS
- No Disclosures